Compare HP Inc (HPQ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Pfizer Inc — how do they compare? HP Inc trades at $28.63 (market cap $26.59B), while Pfizer Inc trades at $26.42 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 5.7× HP Inc's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| HPQ | PFE | |
|---|---|---|
Market Cap | $26.59B | $151.73B |
Sector | Technology | Health |
52-Week High | $30.05 | $28.56 |
52-Week Low | $18.20 | $23.60 |
Enterprise Value | $33.75B | $203.22B |
Dividend Yield | 4.13% | 6.46% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $29.80, down 0.83% on the day, with a bullish technical signal supported by moving averages and positive earnings beats in recent quarters. The company reported Q2 2026 revenue of $14.4B and EPS of $0.86, exceeding expectations, driven by premium product mix and AI-driven efficiencies. Valuation metrics show a P/E of 10.77 and P/S of 0.48, indicating potential undervaluation relative to historical averages.
The outlook remains positive with continued earnings momentum and a 2026 revenue forecast of $57.4B, though risks include PC market volatility and competitive pressures. Analyst consensus is mixed with 29% buy ratings, but technical support at $29 suggests near-term stability. The dividend yield of approximately 4% provides income appeal amid growth initiatives.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
